See more : Transwarranty Finance Limited (TFL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Daré Bioscience, Inc. (DARE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Daré Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Medallion Resources Ltd. (MDL.V) Income Statement Analysis – Financial Results
- Appia Rare Earths & Uranium Corp. (API.CN) Income Statement Analysis – Financial Results
- Maudore Minerals Ltd. (MAOMF) Income Statement Analysis – Financial Results
- Roche Holding AG (0QQ6.L) Income Statement Analysis – Financial Results
- N G Industries LTD (NGIND.BO) Income Statement Analysis – Financial Results
Daré Bioscience, Inc. (DARE)
About Daré Bioscience, Inc.
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.81M | 10.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 766.00K | 0.00 | 80.00K | 6.00K | 625.00K | 305.00K |
| Cost of Revenue | 38.36K | 47.62K | 26.41K | 43.23K | 11.14K | 2.44K | 0.00 | 400.00K | 192.00K | 0.00 | 0.00 | 0.00 | 363.00K |
| Gross Profit | 2.77M | 9.95M | -26.41K | -43.23K | -11.14K | -2.44K | 0.00 | 366.00K | -192.00K | 80.00K | 6.00K | 625.00K | -58.00K |
| Gross Profit Ratio | 98.63% | 99.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 47.78% | 0.00% | 100.00% | 100.00% | 100.00% | -19.02% |
| Research & Development | 21.54M | 30.04M | 30.62M | 20.77M | 8.55M | 6.41M | 984.75K | 27.57M | 25.95M | 11.77M | 9.70M | 15.81M | 13.49M |
| General & Administrative | 12.11M | 11.24M | 8.45M | 6.63M | 5.80M | 5.28M | 2.70M | 10.36M | 11.22M | 8.59M | 6.17M | 6.39M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.11M | 11.24M | 8.45M | 6.63M | 5.80M | 5.28M | 2.70M | 10.36M | 11.22M | 8.59M | 6.17M | 6.39M | 5.34M |
| Other Expenses | 0.00 | 100.00K | 2.52K | 1.51K | 81.05K | 143.50K | 7.49B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 33.61M | 41.39M | 39.07M | 27.40M | 14.34M | 11.69M | 3.69M | 37.92M | 37.17M | 20.36M | 15.87M | 22.20M | 18.82M |
| Cost & Expenses | 33.75M | 41.39M | 39.07M | 27.40M | 14.34M | 11.69M | 3.69M | 37.92M | 37.17M | 20.36M | 15.87M | 22.20M | 19.18M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 10.00K | 9.00K | 2.00K | 2.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 322.63K | 2.24M | 2.43M | 1.08M | 1.49M | 567.00K | 26.00K |
| Depreciation & Amortization | 38.36K | 47.62K | 26.41K | 43.23K | 11.14K | 2.44K | 2.73M | 261.00K | 192.00K | 126.00K | 197.00K | 346.00K | 363.00K |
| EBITDA | -30.90M | -31.36M | -39.04M | -27.36M | -14.33M | -11.69M | -11.18M | -36.81M | -36.97M | -22.13M | -15.46M | -21.19M | -18.55M |
| EBITDA Ratio | -1,100.53% | -313.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,805.09% | 0.00% | -25,180.00% | -261,016.67% | -3,396.32% | -6,082.95% |
| Operating Income | -30.84M | -31.39M | -39.07M | -27.40M | -14.34M | -16.88M | -11.18M | -37.15M | -37.17M | -20.28M | -15.86M | -21.58M | -18.88M |
| Operating Income Ratio | -1,098.33% | -313.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,850.39% | 0.00% | -25,348.75% | -264,333.33% | -3,452.00% | -6,189.51% |
| Total Other Income/Expenses | 678.49K | 437.75K | 372.41K | 1.51K | 81.05K | 143.50K | -322.63K | -2.15M | -2.42M | -3.06M | -1.28M | -526.00K | -64.00K |
| Income Before Tax | -30.16M | -30.95M | -38.70M | -27.40M | -14.26M | -16.74M | -11.50M | -39.31M | -39.59M | -23.34M | -17.14M | -22.10M | -18.94M |
| Income Before Tax Ratio | -1,074.17% | -309.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,131.20% | 0.00% | -29,177.50% | -285,716.67% | -3,536.16% | -6,210.49% |
| Income Tax Expense | 0.00 | -437.75M | -369.89K | -163.07K | -160.72K | 10.23M | -7.17M | 86.00K | 10.00K | 1.08M | 1.49M | 567.00K | 0.00 |
| Net Income | -30.16M | -30.95M | -38.33M | -27.40M | -14.26M | -26.97M | -11.50M | -39.31M | -39.59M | -23.34M | -17.14M | -22.10M | -19.56M |
| Net Income Ratio | -1,074.17% | -309.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,131.20% | 0.00% | -29,177.50% | -285,716.67% | -3,536.16% | -6,414.10% |
| EPS | -4.15 | -4.39 | -7.52 | -10.93 | -10.99 | -30.16 | -3.56 | -14.18 | -15.57 | -16.04 | -9.02 | -280.83 | -267.41 |
| EPS Diluted | -4.15 | -4.39 | -7.52 | -10.93 | -10.99 | -30.16 | -3.56 | -14.18 | -15.57 | -16.04 | -9.02 | -280.83 | -267.41 |
| Weighted Avg Shares Out | 7.28M | 7.05M | 5.10M | 2.51M | 1.30M | 894.37K | 269.36K | 69.21K | 2.54M | 1.45M | 1.90M | 78.70K | 73.16K |
| Weighted Avg Shares Out (Dil) | 7.28M | 7.05M | 5.10M | 2.51M | 1.30M | 894.37K | 269.36K | 69.58K | 0.00 | 1.45M | 1.90M | 78.70K | 73.16K |
Why Dare Bioscience (DARE) Stock Trading Higher On Wednesday?
Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now
Daré Bioscience's (DARE) CEO Sabrina Martucci Johnson on Q1 2021 Results - Earnings Call Transcript
Daré Bioscience Reports First Quarter 2021 Financial Results and Provides a Company Update
Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists
Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2020 Results - Earnings Call Transcript
Dare Bioscience: Q4 Earnings Insights
Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update
Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Daré Bioscience to Participate in Upcoming Virtual Conferences
Source: https://incomestatements.info
Category: Stock Reports